Pantera NV
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pantera NV - overview
Established
2022
Location
-, -, Belgium
Primary Industry
Pharmaceuticals
About
Founded in 2022 and based in Belgium, PanTera NV engages in the production of actinium-225 for targeted cancer therapy. In September 2024, Pantera NV raised EUR 93 million in series A funding led by new investor EQT Life Sciences, with participation from other new investors PMV, Paladin Capital Group, Korys, Eurazeo, Sck Cen, and Kurma Partners. The round was part of a larger EUR 133. 95 million debt and series A funding.
As of 2024, the company is headed by its CEO Sven Van Den Berghe. PanTera focuses on the large-scale production of radiopharmaceuticals. It produces an Ac-225 which is an alpha-emitting radioisotope that helps fight cancers through Targeted Radio Therapy (TRT). This approach enables precise delivery of therapeutic radiation to tumors, minimizing damage to surrounding healthy tissue.
The company plans to use the September 2024 funding to support the construction of a new production facility in Belgium and expand its business opportunities.
Current Investors
Paladin Capital Group, EQT Life Sciences, Eurazeo
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.pantera-life.com/
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Pantera NV - financials
| Fiscal Year Ended | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.